Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients-Reference-Cited by-同舟云学术

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

Published:2016-03-09 Issue:16 Volume:7 Page:21982-21990
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Soverini Simona¹,De Benedittis Caterina¹,Polakova Katerina Machova²,Linhartova Jana²,Castagnetti Fausto¹,Gugliotta Gabriele¹,Papayannidis Cristina¹,Mancini Manuela¹,Klamova Hana²,Salvucci Marzia³,Crugnola Monica⁴,Iurlo Alessandra⁵,Albano Francesco⁶,Russo Domenico⁷,Rosti Gianantonio¹,Cavo Michele¹,Baccarani Michele¹,Martinelli Giovanni¹

Affiliation:

1. Institute of Hematology “L. e A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy

2. Institute of Hematology and Blood Transfusion, Prague, Czech Republic

3. Oncology-Hematology Department, “S. Maria delle Croci” Hospital, Ravenna, Italy

4. Hematology, Parma University Hospital, Parma, Italy

5. Division of Haematology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy

6. Hematology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy

7. Unit of Blood Disease and Stem Cell Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance;International Journal of Molecular Sciences;2023-09-07

2. A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia;Journal of Mass Spectrometry and Advances in the Clinical Lab;2023-04

3. Clinical Cancer Genomic Diagnostics and Modern Diagnostic Pathology;Holland‐Frei Cancer Medicine;2023-02-20

4. From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care;Expert Review of Hematology;2022-11-01

5. PROTAC: targeted drug strategy. Principles and limitations;Russian Chemical Bulletin;2022-11